FibroBiologics, Common Net Worth
FibroBiologics, Common Net Worth Breakdown | FBLG |
FibroBiologics, Common Net Worth Analysis
FibroBiologics, Common's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including FibroBiologics, Common's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of FibroBiologics, Common's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform FibroBiologics, Common's net worth analysis. One common approach is to calculate FibroBiologics, Common's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares FibroBiologics, Common's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing FibroBiologics, Common's net worth. This approach calculates the present value of FibroBiologics, Common's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of FibroBiologics, Common's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate FibroBiologics, Common's net worth. This involves comparing FibroBiologics, Common's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into FibroBiologics, Common's net worth relative to its peers.
Enterprise Value |
|
To determine if FibroBiologics, Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding FibroBiologics, Common's net worth research are outlined below:
| FibroBiologics, Common generated a negative expected return over the last 90 days | |
| FibroBiologics, Common has high historical volatility and very poor performance | |
| FibroBiologics, Common may become a speculative penny stock | |
| Net Loss for the year was (16.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| FibroBiologics, Common generates negative cash flow from operations | |
| FibroBiologics, Common has a poor financial position based on the latest SEC disclosures | |
| About 23.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting |
Follow FibroBiologics, Common's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.41 M.Market Cap |
|
Project FibroBiologics, Common's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.26) | (1.32) | |
| Return On Capital Employed | (3.88) | (3.68) | |
| Return On Assets | (1.26) | (1.32) | |
| Return On Equity | (15.13) | (14.37) |
When accessing FibroBiologics, Common's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures FibroBiologics, Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of FibroBiologics, Common's profitability and make more informed investment decisions.
Evaluate FibroBiologics, Common's management efficiency
FibroBiologics, Common has return on total asset (ROA) of (0.6577) % which means that it has lost $0.6577 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6786) %, meaning that it created substantial loss on money invested by shareholders. FibroBiologics, Common's management efficiency ratios could be used to measure how well FibroBiologics, Common manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.32. The FibroBiologics, Common's current Return On Capital Employed is estimated to increase to -3.68. At this time, FibroBiologics, Common's Total Assets are most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Total Current Assets is estimated to increase to about 11.1 M, while Non Current Assets Total are projected to decrease to roughly 1.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.03 | 0.04 | |
| Tangible Book Value Per Share | 0.03 | 0.04 | |
| Enterprise Value Over EBITDA | (53.10) | (55.75) | |
| Price Book Value Ratio | 679.14 | 713.10 | |
| Enterprise Value Multiple | (53.10) | (55.75) | |
| Price Fair Value | 679.14 | 713.10 | |
| Enterprise Value | 1.1 B | 1 B |
The decision-making processes within FibroBiologics, Common are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroBiologics, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroBiologics, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases FibroBiologics, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ruben Garcia over two months ago Acquisition by Ruben Garcia of 176200 shares of FibroBiologics, Common at 2.36 subject to Rule 16b-3 | ||
O'heeron Pete over three months ago Disposition of 100000 shares by Oheeron Pete of FibroBiologics, Common subject to Rule 16b-3 | ||
O'heeron Pete over three months ago Disposition of 50000 shares by Oheeron Pete of FibroBiologics, Common subject to Rule 16b-3 | ||
Niklas Victoria Ninon Olivia over a year ago FibroBiologics Common exotic insider transaction detected | ||
Cilento Richard C Jr over a year ago FibroBiologics Common exotic insider transaction detected |
FibroBiologics, Common Earnings per Share Projection vs Actual
FibroBiologics, Common Corporate Management
| Ruben JD | General Counsel | Profile | |
| Hamid Khoja | Chief Officer | Profile | |
| CFA CPA | Chief Officer | Profile | |
| Ruben Garcia | General Counsel | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.